Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and purpose: Arsenicals have been used medicinally for decades to treat both infectious disease and cancer. Arsenic trioxide (As 2 O 3) is effective for treatment of acute promyelocytic leukaemia (APL), yet the mechanism of action of this drug is still widely debated. Recently, As 2 O 3 was shown to inhibit the activity of the selenoenzyme thioredoxin reductase (TrxR). TrxR has been proposed to be required for selenium metabolism. The effect of inhibitors of TrxR on selenium metabolism has yet to be assessed. This study aims to determine whether chemotherapeutics that target selenocysteine within selenoenzymes may also affect the metabolism of selenium. Experimental approach: A lung cell line, A549, was used to assess the effect of TrxR inhibitors on selenium metabolism, using 75 Se‐selenite. The level of mRNA encoding cytosolic TrxR (TrxR1) was determined using real‐time reverse transcriptase‐PCR. TrxR activity was determined in whole‐cell extracts. Key results: Exposure of cells to As 2 O 3, arsenite or auranofin led to a concentration‐dependent reduction of selenium metabolism into selenoproteins. Knockdown of TrxR1, using small inhibitory RNA, did not affect selenium metabolism. Exposure of cells to monomethylarsonic acid, a potent inhibitor of TrxR, did not alter selenium metabolism but did inhibit enzyme activity. Conclusions and implications: As 2 O 3 and auranofin block the metabolism of selenium in A549 cells. Because As 2 O 3 is used to treat APL, our findings may reveal the mechanism of this therapeutic action and lead to further research targeting selenium metabolism to find novel chemotherapeutic agents for the treatment of APL. British Journal of Pharmacology (2008) 154, 940–948; doi:10.1038/bjp.2008.161; published online 21 April 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arsenite Causes DNA Damage in Keratinocytes Via Generation of Hydroxyl Radicals
Shi, H., Hudson, L. G., Ding, W., Wang, S., Cooper, K. L., Liu, S., Chen, Y., Shi, X., & Liu, K. J. (2004) · Chemical Research in Toxicology · doi:10.1021/tx049939e · Cited by 159 · cited 2×
“Hydrogen peroxide has been implicated as the primary oxidant that increases upon exposure to arsenite (Pi et al., 2003); however, there is also evidence that superoxide and hydroxyl radicals increase (Shi et al., 2004).”
Background
Cited by
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 673
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Selenium interactions and toxicity: a review
Zwolak, I., & Zaporowska, H. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9203-9 · Cited by 325
Metadata
- Authors
- Talbot, S., Nelson, R., & Self, W. T.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-07
- Volume
- 154
- Issue
- 5
- Pages
- 940-948
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2030421521
- Cited by
- 64
- References
- 1
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia. https://app.cochat.ai/papers/10.1038/bjp.2008.161
- The paper
- Talbot, S., Nelson, R., & Self, W. T. (2008). Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia. British Journal of Pharmacology. https://doi.org/10.1038/bjp.2008.161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.